

# Rheumatology Updates 2023

Erin M. Bauer MD, RhMUS  
2023



# Disclosures

None

# Topics Today

- Polymyalgia Rheumatica / Giant Cell Arteritis
  - Diagnostic Criteria
  - New Meds
    - GCA Guideline Updates
    - Glucocorticoid Induced Osteoporosis Guideline Updates
- Systemic Lupus Erythematosus
  - Updated Classification Criteria
  - New Meds / Treatment modalities
- VEXAS
- 2022 Perioperative guideline
- 2023 Vaccination Guidelines for immunosuppressed patients
- ITIS diet

# Case 1

Ms. A is a 73 year old with well controlled diabetes, hyperlipidemia and hypertension presenting with 3 weeks of sudden onset neck, bilateral shoulder and low back pain.

Most prominent in morning, deep stiffness sensation, will improve with a 2 mile walk and Ibuprofen.

Low grade fevers x 1 week. No weight loss. No joint swelling. No rashes

## Medications:

Metformin 1000 mg BID  
Atorvastatin 40 mg daily  
Lisinopril 40 mg daily  
Amlodipine 5 mg daily


## Exam:

BP: **126/76** HR: **93** Wt: **87.3 kg**  
Gen: uncomfortable, stiff appearing  
Notable for 2+ temporal artery pulses  
Normal respiratory effort  
Heart rate regular, distal pulses 2+  
No rashes  
Myofascial tenderness over trapezius, deltoids, limited overhead reach due to pain. Tender over low back and gluteal area  
No synovitis on exam  
Strength 5/5 proximally and distally

## Differential:

Polymyalgia Rheumatica  
Multifocal local musculoskeletal disease  
Autoimmune/inflammatory myositis  
Rheumatoid Arthritis  
Bone disease  
Paget's, Multiple Myeloma  
Hyperparathyroidism, Osteomalacia  
Drug induced myalgias or myositis  
Statins, Checkpoint inhibitors, Antiretroviral, Antipsychotic meds  
Antimalarial drugs, EtOH, Cocaine  
Fibromyalgia  
Infection (endocarditis, disseminated Lyme, osteomyelitis)  
Spondyloarthropathy  
(Parkinson's, hypothyroidism, malignancy, vasculitis)

# General Approach to PMR



ARTHRITIS & RHEUMATISM  
Vol. 64, No. 4, April 2012, pp 943-954  
DOI 10.1002/art.34356  
© 2012, American College of Rheumatology



© 2012 ACR / EULAR

Which lab test will be the most helpful in this case?

- A. Creatine phosphokinase (CPK)
- B. Antinuclear Antibody (ANA)
- C. Erythrocyte Sedimentation Rate (ESR)
- D. C Reactive Protein (CRP)
- E. Complete Blood Count (CBC)

# Arthritis & Rheumatism

An Official Journal of the American College of Rheumatology  
www.arthritisrheum.org and wileyonlinelibrary.com

## 2012 Provisional Classification Criteria for Polymyalgia Rheumatica

A European League Against Rheumatism/American College of Rheumatology  
Collaborative Initiative

Bhaskar Dasgupta,<sup>1</sup> Marco A. Cimmino,<sup>2</sup> Hilal Maradit Kremers,<sup>3</sup> Wolfgang A. Schmidt,<sup>4</sup>  
Michael Schirmer,<sup>5</sup> Carlo Salvarani,<sup>6</sup> Artur Bachtá,<sup>7</sup> Christian Dejaco,<sup>8</sup> Christina Duftner,<sup>9</sup>  
Hanne Slott Jensen,<sup>10</sup> Pierre Duhaut,<sup>11</sup> Gyula Poór,<sup>12</sup> Novák Pál Kaposi,<sup>12</sup> Peter Mandl,<sup>12</sup>

PMR is almost exclusively a disease of adults **over the age of 50**, with a prevalence that increases progressively with advancing age. The peak incidence of PMR occurs between ages 70 and 80.

PMR is relatively common. The lifetime risk of developing PMR has been estimated at 2.43 percent for women and 1.66 percent for men.

**Women** are affected two to three times more often than men.

Cases of familial aggregation are rare, but recognized.

The annual incidence varies geographically and is highest in **Scandinavian countries** and in people of northern European descent.



**Table 6.** PMR classification criteria scoring algorithm—required criteria: age  $\geq 50$  years, bilateral shoulder aching, and abnormal CRP and/or ESR\*

	Points without US (0–6)	Points with US (0–8)†
Morning stiffness duration >45 minutes	2	2
Hip pain or limited range of motion	1	1
Absence of RF or ACPA	2	2
Absence of other joint involvement	1	1
At least 1 shoulder with subdeltoid bursitis and/or biceps tenosynovitis and/or glenohumeral synovitis (either posterior or axillary) and at least 1 hip with synovitis and/or trochanteric bursitis	NA	1
Both shoulders with subdeltoid bursitis, biceps tenosynovitis, or glenohumeral synovitis	NA	1

\* A score of 4 or more is categorized as polymyalgia rheumatica.

CRP is nearly always elevated in PMR. An **elevated ESR** was noted in **92 to 94 percent of patients** at the time of diagnosis of PMR, while **99 percent** of such patients had an increased serum **CRP level** (greater than 5 mg/L).

Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L, Padula A, Boiardi L. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. *Semin Arthritis Rheum.* 2000 Aug;30(1):17-24. doi: 10.1053/sarh.2000.8366. PMID: 10966209. <https://pubmed.ncbi.nlm.nih.gov/10966209/>

# Case 1

Ms. A is a 73 year old with well controlled diabetes, hyperlipidemia and hypertension presenting with 3 weeks of sudden onset neck, bilateral shoulder and low back pain.

Most prominent in morning, deep stiffness sensation, will improve with a 2 mile walk and Ibuprofen.

Low grade fevers x 1 week. No weight loss. No joint swelling. No rashes

## Laboratory Testing:

ESR: 67 mm/hr

CRP: 50 mg/L

CBC: normal WBCs, mild normocytic anemia, thrombocytosis

CMP: normal renal function, liver enzymes and calcium

CPK: 150 mg/dL

RF/CCP: negative

(TSH, SPEP, PTH, blood cultures, UA)

## Scoring Algorithm with Ultrasound – 3 required criteria: *age ≥50 years, bilateral shoulder aching, abnormal ESR/CRP*

Optional classification criteria	OR (95% CI)	Points
Morning stiffness >45 minutes	5.0 (2.8, 9.1)	2
Hip pain, limited range of motion	1.4 (0.8, 2.6)	1
Normal RF or ACPA	5.2 (2.1, 12.6)	2
Absence of other joint pain	2.2 (1.3, 4.0)	1
<b>ULTRASOUND CRITERIA</b>		
<i>At least 1 shoulder with subdeltoid bursitis and/or biceps tenosynovitis and/or glenohumeral synovitis AND at least 1 hip with synovitis and/or trochanteric bursitis</i>	2.6 (1.3, 5.3)	1
<i>Both shoulders with subdeltoid bursitis, biceps tenosynovitis or glenohumeral synovitis</i>	2.1 (1.2, 3.7)	1

### Optimal cut-off point = 5

- A score 5 had 71% sensitivity and 70% specificity for discriminating all comparison subjects from PMR.
- The specificity was higher (86%) for discriminating shoulder conditions from PMR and lower (65%) for discriminating RA from PMR.
- The c-statistic for the scoring algorithm was 78%.
- A total of 32 (29%) PMR cases and 47 (30%) of comparison subjects were incorrectly classified.

# Imaging in PMR

We now understand PMR to be a distinct chronic inflammatory disease of musculotendinous structure, with differentiating features from other rheumatic diseases most notably its **extra-capsular nature** with associated **peritendon** and **myofascial** inflammation.

- Ultrasound (US)
- Magnetic resonance imaging (MRI)
- Positron emission tomography and computed tomography (PET-CT)

# Case 1

Ms. A is started on 15 mg daily of prednisone.

She feels 99% better after 2 days and calls your office to express her gratitude.

She is tolerating prednisone well

You see her back in clinic 6 weeks later.

## Laboratory Testing:

ESR: 18 mm/hr

CRP: <3 mg/L

## Next steps?

Initial tapering: Taper dose to an oral dose of 10 mg/day prednisone equivalent within **4–8 weeks**.

Tapering once remission is achieved: **Taper daily oral prednisone by 1 mg every 4 weeks** (or by 2.5 mg increments using schedules such as 10/7.5 mg on alternate days, etc.) until discontinuation as long as remission is maintained.

Recommend using a single rather than divided daily doses of oral GCs

# Case 1

Ms. A returns to clinic **6 months** after her initial PMR diagnosis. She had been doing well until about 2 weeks ago when she decrease **prednisone to 7 mg daily**. Now with increased achy shoulder pain and fatigue. No headaches, vision changes, scalp tenderness. Some newer hand stiffness.

## Laboratory Testing:

ESR: 57 mm/hr

CRP: 22 mg/L

## Next steps?

Relapse therapy: Increase oral prednisone to the pre-relapse dose and decrease it gradually (within 4–8 weeks) to the dose at which the relapse occurred.

50% of patients will relapse, most commonly on <10 mg daily

? Methotrexate, IL-6 inhibition

# Future PMR Treatments

## IL-6 inhibitors

- Sarilumab

SAPHYR study: 2 weeks of treatment with SAR 200 mg q 2 weeks + 14 week GC tapered regimen vs placebo Q2W + 52 wk GC tapered regimen. The primary endpoint: proportion of patients achieving sustained remission at wk 52 (disease remission by wk 12, absence of disease flare, CRP normalization from wks 12 to 52 and adherence to the per protocol GC taper from wks 12 to 52)

- Tocilizumab

SEMAPHORE study: Patients randomly assigned to intravenous tocilizumab (8 mg/Kg) (n=51) or placebo (n=50) every 4 weeks for 24 weeks, combined with predefined standardized oral prednisone tapering. The primary efficacy endpoint was CRP PMR-AS < 10 (Min=0-Max 100 with higher values indicating greater activity, no MCID defined) combined with either prednisone  $\leq 5$  mg/day or a  $\geq 10$ -mg prednisone decrease at week 24.

## JAK inhibitors

- Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR) Study: Patients with newly diagnosed PMR were randomized to tofacitinib (5mg bid) group and Glucocorticoids (Pred 15mg/day, gradually tapered) group. All PMR patients underwent clinical and laboratory examinations at 0, 4, 8, 12, 16, 20, and 24 weeks, and PMR activity disease scores (PMR-AS) were also calculated. The primary endpoint was the proportion of patients with PMR-AS  $\leq 10$  at weeks 12 and 24.

# NEWS RELEASE

PRESS RELEASES

MEDIA STATEMENTS

## **REGENERON**<sup>®</sup>

February 28, 2023 at 8:00 PM EST



[« Back](#) 


### **KEVZARA<sup>®</sup> (SARILUMAB) APPROVED BY FDA AS FIRST AND ONLY BIOLOGIC INDICATED FOR PATIENTS WITH POLYMYALGIA RHEUMATICA**

**Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial**

**Kevzara now approved to treat two chronic inflammatory disorders**

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara<sup>®</sup> (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.

**Figure. Summary of disease remission, disease flare, CRP reduction, and adherence to prednisone taper**



SAR + 14 week GC taper demonstrated significant efficacy vs the comparator arm in steroid refractory PMR patients, including clinically meaningful improvement in quality of life.

Safety was consistent with the known safety profile of SAR.

CI, confidence interval; EQ-5D, EuroQol 5-dimension questionnaire; FACIT-Fatigue, functional assessment of chronic illness therapy fatigue scale; HAQ-DI, Health Assessment Questionnaire Disability Index; MD-VAS, physician global assessment of disease activity-Visual Analog Scale; SD, standard deviation; SF-36, short form 36-item questionnaire.



Dasgupta B, Unizony S, Warrington KJ, *et al*  
 LB0006 SARILUMAB IN PATIENTS WITH RELAPSING POLYMYALGIA RHEUMATICA: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL (SAPHYR)  
*Annals of the Rheumatic Diseases* 2022;81:210-211.  
[https://ard.bmj.com/content/81/Suppl\\_1/210.1](https://ard.bmj.com/content/81/Suppl_1/210.1)

## COMMON ADVERSE REACTIONS IN PRE-RESCUE, PLACEBO-CONTROLLED TRIALS<sup>1\*</sup>

Preferred Term	Placebo + DMARD(s) N=579	KEVZARA 150 mg +DMARD(s) N=579	KEVZARA 200 mg +DMARD(s) N=582
Neutropenia	0.2%	7%	10%
ALT increased	2%	5%	5%
Injection site erythema	0.9%	5%	4%
Injection site pruritus	0.2%	2%	2%
Upper respiratory tract infection	2%	4%	3%
Urinary tract infection	2%	3%	3%
Hypertriglyceridemia	0.5%	3%	1%
Leukopenia	0%	0.9%	2%

\*Adverse reactions occurring in  $\geq 2\%$  of patients administered KEVZARA 200 mg or KEVZARA 150 mg + DMARD(s) and greater than observed in patients on placebo + DMARD(s).

- Medically relevant AE occurring at an incidence of less than 2% in patients with RA treated with KEVZARA in controlled studies was oral herpes<sup>1</sup>
- Decrease in ANC was not associated with higher incidence of infections, including serious infections<sup>1</sup>
- In the long-term safety population, the overall rates of serious infections, GI perforations, neutrophil counts, platelet counts, and lipid parameters were consistent with what was observed in the placebo-controlled trials<sup>1</sup>

Dasgupta B, Unizony S, Warrington KJ, *et al*  
 LB0006 SARILUMAB IN PATIENTS WITH RELAPSING POLYMYALGIA RHEUMATICA: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL (SAPHYR)  
*Annals of the Rheumatic Diseases* 2022;**81**:210-211.

# Case 2

Ms. B is a 77 year old with well controlled diabetes, hyperlipidemia and hypertension who was diagnosed with PMR about 1 month ago by her primary care physician. She started on prednisone 10 mg daily with initial improvement in her symptoms.

She ran out of prednisone 2 weeks ago and is now in clinic with return of hip and shoulder girdle symptoms. Newer severe headaches primarily over the right temple with some tingling over the whole scalp.

## Laboratory Testing:

ESR: 78 mm/hr

CRP: 55 mg/L

CBC: normal WBCs, mild normocytic anemia, thrombocytosis

CMP: normal renal function, liver enzymes and calcium

Glucose of 290 mg/dL

CPK: 150 mg/dL

RF/CCP: negative

## Audience Poll

What percentage of patients with PMR will develop GCA?

- A. 1-2%
- B. 10-20 %
- C. 30-40%
- D. >50%

## Giant Cell Arteritis

About **10-20 percent of PMR patients** will experience GCA at some point. PMR can precede, accompany, or follow GCA

PMR occurs in approximately **50 percent** of patients with GCA

Only **4 percent** of patients with GCA have both the ESR and CRP in the normal range

# 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis

Cristina Ponte <sup>1,2</sup> Peter C Grayson <sup>3</sup> Joanna C Robson,<sup>4,5</sup> Ravi Suppiah,<sup>6</sup> Katherine Bates Gribbons,<sup>3</sup> Andrew Judge <sup>7,8,9</sup> Anthea Craven <sup>7</sup> Sara Khalid,<sup>7</sup> Andrew Hutchings <sup>10</sup> Richard A Watts <sup>7,11</sup> Peter A Merkel <sup>12</sup> Raashid A Luqmani <sup>7</sup> For the DCVAS Study Group

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/ard-2022-223480>).

For numbered affiliations see end of article.

## Correspondence to

Professor Peter A Merkel  
Rheumatology, University of Pennsylvania, Philadelphia, PA 19104, USA;  
[pmerkel@upenn.edu](mailto:pmerkel@upenn.edu)

This article is published simultaneously in *Arthritis & Rheumatology*.

Received 13 October 2022  
Accepted 13 October 2022  
Published Online First  
9 November 2022

## ABSTRACT

**Objective** To develop and validate updated classification criteria for giant cell arteritis (GCA).

**Methods** Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in six phases: (1) identification of candidate items, (2) prospective collection of candidate items present at the time of diagnosis, (3) expert panel review of cases, (4) data-driven reduction of candidate items, (5) derivation of a points-based risk classification score in a development data set and (6) validation in an independent data set.

**Results** The development data set consisted of 518 cases of GCA and 536 comparators. The validation data set consisted of 238 cases of GCA and 213 comparators. Age  $\geq 50$  years at diagnosis was an absolute requirement for classification. The final criteria items and weights were as follows: positive temporal artery biopsy or temporal artery halo sign on ultrasound (+5); erythrocyte sedimentation rate  $\geq 50$  mm/hour or C reactive protein  $\geq 10$  mg/L (+3); sudden visual loss (+3); morning stiffness

widespread use of non-invasive and advanced vascular imaging modalities, which have become increasingly incorporated in the clinical assessment of GCA. Vascular ultrasound can be used to diagnose GCA, and depending on the clinical setting, a non-compressible ‘halo’ sign of a temporal  $\pm$  axillary artery may replace the need for temporal artery biopsy (TAB).<sup>5-8</sup> Moreover, vascular imaging has demonstrated that arterial involvement in GCA is not exclusively confined to the cranial arteries<sup>9 10</sup> and can commonly affect the aorta and primary branches in a pattern similar to Takayasu arteritis (TAK).<sup>11 12</sup>

The limitations of the ACR 1990 criteria for GCA have become more apparent in the conduct of recent clinical trials and other research studies, in which investigators typically modify the 1990 ACR criteria to reflect modern practice.<sup>6 13 14</sup> Notably, the 1990 ACR criteria focus mostly on cranial features of GCA and do not perform well in classifying patients with disease predominantly affecting

CLASSIFICATION CRITERIA FOR **GIANT CELL ARTERITIS****CONSIDERATIONS WHEN APPLYING THESE CRITERIA**

- These classification criteria should be applied to classify the patient as having giant cell arteritis when a diagnosis of medium-vessel or large-vessel vasculitis has been made
- Alternate diagnoses mimicking vasculitis should be excluded prior to applying the criteria

**ABSOLUTE REQUIREMENT**

Age  $\geq$  50 years at time of diagnosis

**ADDITIONAL CLINICAL CRITERIA**

Morning stiffness in shoulders/neck	+2
Sudden visual loss	+3
Jaw or tongue claudication	+2
New temporal headache	+2
Scalp tenderness	+2
Abnormal examination of the temporal artery <sup>1</sup>	+2

**LABORATORY, IMAGING, AND BIOPSY CRITERIA**

Maximum ESR $\geq$ 50 mm/hour or maximum CRP $\geq$ 10 mg/liter <sup>2</sup>	+3
Positive temporal artery biopsy or halo sign on temporal artery ultrasound <sup>3</sup>	+5
Bilateral axillary involvement <sup>4</sup>	+2
FDG-PET activity throughout aorta <sup>5</sup>	+2

**Sum the scores for 10 items, if present. A score of  $\geq$  6 points is needed for the classification of **GIANT CELL ARTERITIS**.**

# Temporal Artery Biopsy

Within two weeks of starting treatment


Initial unilateral biopsy of at least 1 cm

Sensitivity of the temporal artery biopsy ranges from **50 to 95%**  
In a large meta-analysis including 3092 patients, the diagnostic sensitivity of the temporal artery biopsy was found to be **77%**

The increased yield of contralateral biopsy for the diagnosis ~5%

Rarely, temporal artery biopsy will disclose pathology other than GCA, such as systemic necrotizing vasculitis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, polyarteritis nodosa, amyloidosis, or lymphoma

Rubenstein E, Maldini C, Gonzalez-Chiappe S, Chevret S, Mahr A. Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis. *Rheumatology (Oxford)*. 2020 May 1;59(5):1011-1020. doi: 10.1093/rheumatology/kez385.  
<https://pubmed.ncbi.nlm.nih.gov/31529073/>




**Figure 1:** Normal temporal artery biopsy (left) as opposed to a temporal artery biopsy from a patient with giant-cell arteritis (right) disclosing typical transmural mononuclear cell infiltration, internal elastic lamina breakdown and intimal hyperplasia. Double head arrow remarks the thickened intima and single head arrows indicate the presence of giant-cells. Haematoxylin-eosin staining. L: lumen; I: intima; M: media; Adv: adventitia.








# Ultrasound in GCA

Must be done within one week

“**Halo sign**”- 0.3 to 2.0 mm hypoechoogenic, is highly specific for GCA. The “**compression sign**” also has high specificity for the



Skoog J, Svensson C, Eriksson P, Sjöwall C and Zachrisson H (2022) The Diagnostic Performance of an Extended Ultrasound Protocol in Patients With Clinically Suspected Giant Cell Arteritis. *Front. Med.* 8:807996



# US for *screening* of GCA in PMR patients

ABSTRACT NUMBER: 0478

## Sonographic Prevalence of Subclinical GCA in Newly Diagnosed PMR

Colm Kirby<sup>1</sup>, Rachael Flood<sup>1</sup>, Ronan Mullan<sup>1</sup>, Grainne Murphy<sup>2</sup> and David Kane<sup>1</sup>,  
<sup>1</sup>Tallaght University Hospital, Dublin, Ireland, <sup>2</sup>Cork University Hospital, Cork, Ireland

Meeting: ACR Convergence 2022

Keywords: giant cell arteritis, Imaging, Polymyalgia Rheumatica (PMR), Ultrasound

Favorite ☆

Tweet

Share 0

Share

Email

Print

### SESSION INFORMATION

**Date:** Saturday, November 12, 2022

**Session Type:** Poster Session A

**Session Title:** Vasculitis – Non-ANCA-Associated and Related Disorders

**Session Time:** 1:00PM-3:00PM

**Poster I:** Giant Cell Arteritis


**Background/Purpose:** It has been reported that 20-50% of patients with PMR have subclinical GCA. The natural history of US-defined subclinical GCA in PMR is not known.

**Twenty five newly-diagnosed PMR** patients who met a clinical diagnosis for PMR, verified by 2 rheumatologists, were examined by US. US of all 6 branches of the superficial temporal arteries and both axillary arteries

**Five patients (20%)** were identified as having subclinical GCA on US (5/5 met 2012 ACR/EULAR PMR classification criteria, 0/5 met ACR GCA classification criteria). Temporal artery involvement was identified in 5/5, with axillary involvement in 1/5.

## 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis


Mehrdad Maz,<sup>1</sup> Sharon A. Chung,<sup>2</sup> Andy Abril,<sup>3</sup> Carol A. Langford,<sup>4</sup> Mark Gorelik,<sup>5</sup> Gordon Guyatt,<sup>6</sup>



**IV pulse GCs:** IV methylprednisolone 500–1,000 mg/day equivalent for 3–5 days

**High-dose oral GCs:** Prednisone 1 mg/kg/day up to 80 mg or equivalent

### Overview of treatment of giant cell arteritis (GCA)



ABA = abatacept, AZA = azathioprine, GC = glucocorticoids, IV = intravenous, MTX = methotrexate, TCZ = tocilizumab

**Table 3.** Recommendations/statements for treatment (medical management and surgical intervention) and clinical/laboratory monitoring in GCA\*

Recommendation/statement	GCA PICO question informing recommendation and discussion	Level of evidence
Medical management		
Recommendation: For patients with newly diagnosed GCA without manifestations of cranial ischemia, we conditionally recommend initiating treatment with high-dose oral GCs over IV pulse GCs.	11	Very low to low
Recommendation: For patients with newly diagnosed GCA with threatened vision loss, we conditionally recommend initiating treatment with IV pulse GCs over high-dose oral GCs.	12	Very low
Recommendation: For patients with newly diagnosed GCA, we conditionally recommend dosing oral GCs daily over an alternate-day schedule.	18	Low
Recommendation: For patients with newly diagnosed GCA, we conditionally recommend initiating treatment with high-dose oral GCs over moderate-dose oral GCs.	14	Very low to low
Recommendation: For patients with newly diagnosed GCA, we conditionally recommend the use of oral GCs with tocilizumab over oral GCs alone.	15, 16, 17	Low to high
Recommendation: For patients with GCA with active extracranial large vessel involvement, we conditionally recommend treatment with oral GCs combined with a non-GC immunosuppressive agent over oral GCs alone.	21	Very low to low
Ungraded position statement: The optimal duration of therapy with GCs for GCA is not well established and should be guided by the patient's values and preferences.	20	Low to moderate
Recommendation: In patients with newly diagnosed GCA, we conditionally recommend <i>against</i> the use of an HMG-CoA reductase inhibitor ("statin") specifically for the treatment of GCA.	19	Very low
Recommendation: For patients with GCA who have critical or flow-limiting involvement of the vertebral or carotid arteries, we conditionally recommend adding aspirin.	13	Very low to moderate
Recommendation: For patients with GCA who experience disease relapse while receiving moderate-to-high-dose GCs, we conditionally recommend adding a non-GC immunosuppressive drug.	Relapse 2	†
Recommendation: For patients with GCA who experience disease relapse with symptoms of cranial ischemia, we conditionally recommend adding a non-GC immunosuppressive agent and increasing the dose of GCs over increasing the dose of GCs alone.	Relapse 1, 3	†
Recommendation: For patients with GCA who experience disease relapse with symptoms of cranial ischemia while receiving GCs, we conditionally recommend adding tocilizumab and increasing the dose of GCs over adding methotrexate and increasing the dose of GCs.	Relapse 4	†

FDA NEWS RELEASE

# FDA approves first drug to specifically treat giant cell arteritis



[More Press Announcements](#)

**For Immediate Release:** May 22, 2017

[Español](#)

The U.S. Food and Drug Administration today expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the first FDA-approved therapy, specific to this type of vasculitis.

“We expedited the development and review of this application because this drug fulfills a critical need for patients with this serious disease who had limited treatment options,” said Badrul Chowdhury, M.D., Ph.D., director of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research.

**Content current as of:**  
03/28/2018

**Follow FDA**  
[Follow @US\\_FDA](#)  
[Follow FDA](#)  
[Follow @FDAmedia](#)

**2022 American College of Rheumatology Guideline for the  
Prevention and Treatment of Glucocorticoid-Induced Osteoporosis**

Recommend risk stratifying patients via FRAX score

For all adults initiating or continuing **GC therapy  $\geq$  2.5mg/day for > 3 months**, who have never had fracture risk assessment or been treated with OP therapy, initial clinical fracture risk assessment is strongly recommended

**Clinical fracture risk factor assessment** includes the dose, duration, and pattern of GC use, alcohol use, smoking history, hypogonadism, history of prior fractures, low body weight, significant weight loss, parental history of hip fracture, fall history, thyroid disease, hyperparathyroidism, rheumatoid arthritis, malabsorption, chronic liver disease, inflammatory bowel disease, and height loss.

If available, **BMD testing is recommended within 6 months of starting GC therapy for adults and every 1-2 years thereafter while continuing GC therapy.**

**Table 2. Recommendations for initial treatment for prevention of GIOP in adults beginn  
GC therapy**

Recommendations for patients taking prednisone $\geq$ 2.5mg/day for > 3months	Certainty of evidence	PICO evidence report basis
For adults and children beginning or continuing chronic GC treatment at low, moderate, or high risk of fracture, optimizing dietary and supplemental calcium and vitamin D in addition to lifestyle modifications (CAL/VIT D/LM) is <b>conditionally</b> recommended. All additional recommendations are in addition to CAL/VIT D/LM).	Low or Very Low	1.1a,b,c-1.3a,b,c, 2.1-2.3, 7.16-7.26
<b>In adults <math>\geq</math> 40 years</b>		
With <b>LOW</b> fracture risk, adding any OP medications to CAL/VIT D /LM based on known harms with no evidence of benefit is <b>strongly</b> recommended <b>against</b> .	Very Low	1.4a-1.28a
With <b>MODERATE</b> fracture risk, oral or IV BP, PTH/PTHrP, or DEN over no OP therapy is <b>conditionally</b> recommended.	Moderate to Very Low	1.4b-1.28b
With <b>MODERATE</b> fracture risk, using ROM or SERM is <b>conditionally</b> recommended <b>against</b> except for in patients intolerant of other agents, due to risk of life-threatening harms.	Very Low	1.12b, 1.16b,1.17b,1.21 b-1.25b, 1.28b
With <b>HIGH</b> fracture risk, oral BP over not giving OP therapy is <b>strongly</b> recommended <sup>#</sup> . IV BP, PTH/PTHrP, or DEN over no OP therapy is <b>conditionally</b> recommended <sup>5</sup> .	Low or Very Low	1.5c-1.28c
With <b>HIGH</b> fracture risk, using ROM or SERM is <b>conditionally</b> recommended <b>against</b> except for patients intolerant of other agents due to risk of life- threatening harms	Very Low	1.16c, 1.21c, 1.28c

# Lupus Updates

## Criteria

### 2019 European League Against Rheumatism/ American College of Rheumatology classification criteria for systemic lupus erythematosus

Martin Aringer,<sup>1</sup> Karen Costenbader,<sup>2</sup> David Daikh,<sup>3</sup> Ralph Brinks,<sup>4</sup> Marta Mosca,<sup>5</sup> Rosalind Ramsey-Goldman,<sup>6</sup> Josef S Smolen,<sup>7</sup> David Wofsy,<sup>8</sup> Dimitrios T Boumpas,<sup>9,10</sup> Diane L Kamen,<sup>11</sup> David Jayne,<sup>12</sup> Ricard Cervera,<sup>13</sup> Nathalie Costedoat-Chalumeau,<sup>14</sup> Betty Diamond,<sup>15</sup> Dafna D Gladman,<sup>16</sup> Bevra Hahn,<sup>17</sup> Falk Hiepe,<sup>18</sup> Søren Jacobsen,<sup>19</sup> Dinesh Khanna,<sup>20</sup> Kirsten Lerstrøm,<sup>21</sup> Elena Massarotti,<sup>22,23</sup> Joseph McCune,<sup>24</sup> Guillermo Ruiz-Irastorza,<sup>24</sup> Jorge Sanchez-Guerrero,<sup>25,26</sup> Matthias Schneider,<sup>27</sup> Murray Urowitz,<sup>28</sup> George Bertias,<sup>29</sup> Bimba F Hoyer,<sup>18,30</sup> Nicolai Leuchten,<sup>1</sup> Chiara Tani,<sup>31</sup> Sara K Tedeschi,<sup>23,32</sup> Zahi Touma,<sup>33</sup> Gabriela Schmajuk,<sup>3</sup> Branimir Anic,<sup>34</sup> Florence Assan,<sup>35</sup> Tak Mao Chan,<sup>36</sup> Ann Elaine Clarke,<sup>37</sup> Mary K Crow,<sup>38</sup> László Czirják,<sup>39</sup> Andrea Doria,<sup>40</sup> Winfried Graninger,<sup>41</sup> Bernadett Halda-Kiss,<sup>39</sup> Sarfaraz Hasni,<sup>42</sup> Peter M Izmirly,<sup>43</sup> Michelle Jung,<sup>37</sup> Gábor Kumánovics,<sup>39</sup> Xavier Mariette,<sup>44,45</sup> Ivan Padjen,<sup>34</sup> José M Pego-Reigosa,<sup>46</sup> Juanita Romero-Diaz,<sup>47</sup> Íñigo Rúa-Figueroa Fernández,<sup>48</sup> Raphaële Seror,<sup>35</sup> Georg H Stummvoll,<sup>49</sup> Yoshiya Tanaka,<sup>50</sup> Maria G Tektonidou,<sup>51</sup> Carlos Vasconcelos,<sup>52</sup> Edward M Vital,<sup>53,54</sup> Daniel J Wallace,<sup>55</sup> Sule Yavuz,<sup>56</sup> Pier Luigi Meroni,<sup>57</sup> Marvin J Fritzler,<sup>58</sup> Ray Naden,<sup>59</sup> Thomas Dörner,<sup>18</sup> Sindhu R Johnson,<sup>60,61</sup>

Handling editor David S Pisetsky

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2018-214819>).

For numbered affiliations see end of article.

#### ABSTRACT

clinical musculoskeletal renal and three immunological

**Figure 2** Classification criteria for systemic lupus erythematosus.

§Additional criteria items within the same domain will not be counted.

\*Note: In an assay with at least 90% specificity against relevant disease controls.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827566/>

Entry criterion		
Antinuclear antibodies (ANA) at a titer of $\geq 1:80$ on HEp-2 cells or an equivalent positive test (ever)		
↓		
If absent, do not classify as SLE If present, apply additive criteria		
↓		
Additive criteria		
Do not count a criterion if there is a more likely explanation than SLE. Occurrence of a criterion on at least one occasion is sufficient. SLE classification requires at least one clinical criterion and $\geq 10$ points. Criteria need not occur simultaneously.		
Within each domain, only the highest weighted criterion is counted toward the total score§.		
Clinical domains and criteria	Weight	Immunology domains and criteria Weight
<b>Constitutional</b>		<b>Antiphospholipid antibodies</b>
Fever	2	Anti-cardiolipin antibodies OR Anti- $\beta 2$ GP1 antibodies OR Lupus anticoagulant 2
<b>Hematologic</b>		<b>Complement proteins</b>
Leukopenia	3	Low C3 OR low C4 3
Thrombocytopenia	4	Low C3 AND low C4 4
Autoimmune hemolysis	4	
<b>Neuropsychiatric</b>		<b>SLE-specific antibodies</b>
Delirium	2	Anti-dsDNA antibody* OR Anti-Smith antibody 6
Psychosis	3	
Seizure	5	
<b>Mucocutaneous</b>		
Non-scarring alopecia	2	
Oral ulcers	2	
Subacute cutaneous OR discoid lupus	4	
Acute cutaneous lupus	6	
<b>Serosal</b>		
Pleural or pericardial effusion	5	
Acute pericarditis	6	
<b>Musculoskeletal</b>		
Joint involvement	6	
<b>Renal</b>		
Proteinuria $>0.5\text{g}/24\text{h}$	4	
Renal biopsy Class II or V lupus nephritis	8	
Renal biopsy Class III or IV lupus nephritis	10	
<b>Total score:</b>		
↓		

Classify as Systemic Lupus Erythematosus with a score of 10 or more if entry criterion fulfilled.

# When to Order an ANA

- Do you think this patient has an ANA associated Rheumatologic condition?
  1. SLE / drug induced lupus
  2. Scleroderma
  3. Autoimmune Myositis (polymyositis, dermatomyositis)
  4. Sjogrens
- Is this a young person with Raynaud's or older person with new Raynaud's
- New JIA diagnosis

# Updates: Lupus management

Medication	Mechanism of action	Indication	Considerations for use	Side Effects/Monitoring
Belimumab (Benlysta)  Approved 2020 for LN	B-lymphocyte stimulator ( <b>BLyS</b> ) inhibitor  IV monthly or SQ weekly	SLE  Lupus Nephritis	Rash and joint predominant SLE  Nephritis that has failed MMF	Infection Diarrhea <b>Depression?</b>  (\$2,288.78/ month)
Anifrolumab-fnia (Saphnelo)  Approved 2021	Interferon Receptor Antagonist  IV Monthly	SLE	?	Infection Hypersensitivity  (\$2,760.33/month)
Voclosporin (Lupkynis)  Approved 2021	Calcineurin Inhibitor  PO BID	Lupus Nephritis	?	Hypertension Diarrhea Prolonged QT interval  (\$5,000/month)

# Hematopoietic stem cell transplantation in SLE

The basic principle of HSCT is to achieve a broad immune depletion, providing an initial “debulking” of the immunologic memory repertoire

- Memory T and B lymphocytes


- Plasma cells

To date, more than 300 patients have received autologous HSCT specifically for SLE


Pooled data from the largest 15 single-center experiences and multicenter trials with 339 patients included indicate a **disease free survival of 50% to 66% at 5 years** despite discontinuation of immunosuppressive and other targeted disease-modifying treatment

Matteo Doglio et al. New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies, *Journal of Allergy and Clinical Immunology* Volume 150, Issue 6, 2022, Pages 1289-1301. <https://doi.org/10.1016/j.jaci.2022.08.003> <https://www.sciencedirect.com/science/article/pii/S0091674922010569>

## SLE Auto-HSCT, 1996-2020 n=112



Pediatrics (<18 years at transplant) n = 18 (16%) - Adults n = 93 (84%)



**FIG 2.** Number of HSCTs for SLE. **A.** The frequency of autologous HSCTs for SLE from 1996 to 2020 included in the EBMT registry. The overall number of pediatric and adult patients is reported. **B.** The number of HSCTs for SLE by country from 1996 to 2020. *Auto-HSCT*, Autologous HSCT.

Treatment-related mortality gradually declined from 12% in the first EBMT registry survey in 2004 to less than 5% in most recent reports between 2017 and 2019

Potential candidates for HSCT would reasonably include those with sustained or relapsed steroid dependence after at least 6 months of the best standard therapy, using mycophenolate mofetil or CYC with or without mAbs, with documented evidence of visceral involvement or refractory SLE

## NIH RESEARCH MATTERS

February 14, 2023

# VEXAS syndrome more common than realized

### At a Glance

- A severe inflammatory disease called VEXAS is more prevalent and has a broader range of symptoms than expected.
- Additional studies of racially diverse populations are needed to better understand the scope and symptoms of this hard-to-recognize disease.

In 2020, a team of NIH researchers reported the discovery of a rare and often-deadly inflammatory disorder, which they named VEXAS. Affected people have varying symptoms that can include anemia, recurrent fevers, painful rashes, blood clots, and shortness of breath. Because these symptoms overlap with other autoimmune and inflammatory diseases, VEXAS can be hard to recognize. But having an accurate diagnosis is important for effective treatment.



The study suggests that VEXAS disease, which was only recently discovered, may be more common than previously thought. *Lucky Business / Shutterstock*

VEXAS was discovered by searching for genetic variants that were shared among more than 2,500 patients with body-wide inflammation or other unusual and undiagnosed conditions. The identified gene, *UBA1*, is on the X chromosome, and all 25 people initially diagnosed with VEXAS were male. Since men have only one X chromosome, they only have one copy of the gene. Women typically have two X chromosomes and therefore two copies of *UBA1*. In women, a mutation in only one copy is likely to cause less severe or no disease. The genetic mutations that cause this disease occur after birth and so aren't transmitted from parents to children.

### Head & Neck:

- Fever
- Inflammatory eye disease
- Periorbital edema
- Ear chondritis
- Nose chondritis
- Sensorineural hearing loss

### Thorax:

- Pleural effusion
- Neutrophilic alveolitis
- Myocarditis

### Bone marrow:

- Myelodysplastic syndrome
- Multiple myeloma
- Cytopenias
- Vacuoles in myeloid and erythroid cells

### Abdomen:

- Hepatosplenomegaly
- Colitis

### Musculoskeletal:

- Inflammatory arthritis

### Pelvis:


- Orchitis/epididymitis

### Cutaneous:

- Neutrophilic Dermatitis
- Medium-vessel vasculitis
- Leukocytoclastic vasculitis

### Lower extremities:

- Deep vein thrombosis




# VEXAS

VEXAS syndrome is a disease that causes inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the *UBA1* gene of blood cells and acquired later in life. Patients do not pass the disease to their children.

## What does VEXAS mean?

VEXAS is an acronym defined as follows:

- V** - **v**acuoles are often seen in cells identified in bone marrow biopsies from patients with VEXAS
- E** - **E1** ubiquitin activating enzyme, encoded by the *UBA1* gene which is mutated in patients.
- X** - the *UBA1* gene is located on the **X** chromosome.
- A** - patients have **a**utoinflammation.
- S** - the mutations are **s**omatic, meaning they are acquired at some point in life and not inherited.



# VEXAS

Patients with VEXAS can have a wide range of inflammatory symptoms affecting multiple organs including:

- skin (rashes that can be painful).
- cartilaginous structures (pain and swelling of the ear and nose).
- lungs (cough and shortness of breath).
- joints (swelling and pain).
- vasculature (inflammation of vessels).

Patients often have fever and extreme fatigue. The hematologic features can include anemia, low platelets, and blood clots.

On many occasions patients with VEXAS have associated clinical diagnoses, including relapsing polychondritis, polyarteritis nodosa, sweet syndrome and myelodysplastic syndrome.

There is no standardized treatment for VEXAS currently, however the inflammatory features can be treated with steroids and other immunosuppressants. Some patients may be candidates for bone marrow transplantation.

## 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty

### Guideline Summary

Updated March 17, 2022

*This updated guideline includes changes in the recommendations regarding rituximab and belimumab for patients with severe SLE, and now includes anifrolumab and voclosporin. For patients with spondyloarthritis, recommendations have been added on management of ixekizumab and guselkumab. The recommendations have changed for management of JAK inhibitors and suggest withholding for 3 days before surgery; tofacitinib, upadacitinib, and baricitinib are now included.*

This updated guideline addresses the perioperative management of disease modifying medications for adults with rheumatic diseases, specifically inflammatory arthritis (IA) and systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) and total knee arthroplasty (TKA). A panel of rheumatologists, orthopaedic surgeons, and infectious disease specialists updated the systematic literature review and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions, updating the 2017 recommendations\*. As patients with IA and SLE are at increased risk of infection after THA and TKA, these recommendations aim to balance the risk of perioperative infection and the risk of disease flares, recognizing that all flares have an impact on quality of life but a flare in a patient with severe SLE at risk for organ damage warrants unique considerations. This updated guideline includes recently introduced immunosuppressive medications to help decision-making by clinicians and patients regarding perioperative disease modifying medication management for patients with IA and SLE at the time of elective THA or TKA.

**MEDICATIONS TO CONTINUE THROUGH SURGERY**

<b>DMARDs: CONTINUE these medications through surgery. (All patients)</b>	<b>Dosing Interval</b>	<b>Recommended timing of surgery since last medication dose</b>
Methotrexate	Weekly	Anytime
Sulfasalazine	Once or twice daily	Anytime
Hydroxychloroquine	Once or twice daily	Anytime
Leflunomide (Arava)	Daily	Anytime
Doxycycline	Daily	Anytime
<b><i>Apremilast (Otezla)</i></b>	<b><i>Twice daily</i></b>	<b><i>Anytime</i></b>
<b>SEVERE SLE-SPECIFIC MEDICATIONS††: CONTINUE these medications in the perioperative period in consultation with the treating rheumatologist.</b>	<b>Dosing Interval</b>	<b>Recommended timing of surgery since last medication dose</b>
Mycophenolate mofetil	Twice daily	Anytime
Azathioprine	Daily or twice daily	Anytime
Cyclosporine	Twice daily	Anytime
Tacrolimus	Twice daily (IV and PO)	Anytime
<b><i>Rituximab (Rituxan)</i></b>	<b><i>IV Every 4-6 months</i></b>	<b><i>Month 4-6</i></b>
<b><i>Belimumab (Benlysta)</i></b>	<b><i>Weekly SQ</i></b>	<b><i>Anytime</i></b>
<b><i>Belimumab (Benlysta)</i></b>	<b><i>Monthly IV</i></b>	<b><i>Week 4</i></b>
<b><i>Anifrolumab (Saphnelo)†</i></b>	<b><i>IV Every 4 weeks</i></b>	<b><i>Week 4</i></b>
<b><i>Voclosporin (Lupkynis)†</i></b>	<b><i>Twice daily</i></b>	<b><i>Continue</i></b>



**MEDICATIONS TO WITHHOLD PRIOR TO SURGERY\*\*\***

<b>BIOLOGICS: WITHHOLD these medications through surgery</b>		<b>Recommended timing of surgery since last medication dose</b>
Infliximab (Remicade)	Every 4, 6, or 8 weeks	Week 5, 7, or 9
Adalimumab (Humira)	Every 2 weeks	Week 3
Etanercept (Enbrel)	Every week	Week 2
Abatacept (Orencia)	Monthly (IV) or weekly (SQ)	Week 5 Week 2
Certolizumab (Cimzia)	Every 2 or 4 weeks	Week 3 or 5
Rituximab (Rituxan)	2 doses 2 weeks apart every 4-6 months	Month 7
Tocilizumab (Actemra)	Every week (SQ) or every 4 weeks (IV)	Week 2 Week 5
Anakinra (Kineret)	Daily	Day 2
IL-17-Secukinumab (Cosentyx)	Every 4 weeks	Week 5
Ustekinumab (Stelara)	Every 12 weeks	Week 13
<b><i>Ixekizumab (Taltz)†</i></b>	<b><i>Every 4 weeks</i></b>	<b><i>Week 5</i></b>
<b><i>IL-23 Guselkumab (Tremfya)†</i></b>	<b><i>Every 8 weeks</i></b>	<b><i>Week 9</i></b>
<b><i>JAK inhibitors WITHHOLD this medication 3 days prior to surgery**</i></b>		
<b><i>Tofacitinib (Xeljanz):</i></b>	<b><i>Daily or twice daily</i></b>	<b><i>Day 4</i></b>
<b><i>Baricitinib (Olumiant)†</i></b>	<b><i>Daily</i></b>	<b><i>Day 4</i></b>
<b><i>Upadacitinib (Rinvoq)†</i></b>	<b><i>Daily</i></b>	<b><i>Day 4</i></b>
<b>NOT-SEVERE SLE: WITHHOLD these medications 1 week prior to surgery</b>	<b>Dosing Interval</b>	<b>1 week after last dose</b>
Mycophenolate mofetil	Twice daily	<b>1 week after last dose</b>
Azathioprine	Daily or twice daily	1 week after last dose
Cyclosporine	Twice daily	<b>1 week after last dose</b>
Tacrolimus	Twice daily (IV and PO)	<b>1 week after last dose</b>
Rituximab (Rituxan)	Every 4-6 months	Month 7
<b><i>Belimumab IV (Benlysta)</i></b>	<b><i>Monthly</i></b>	<b><i>Week 5</i></b>
<b><i>Belimumab SQ (Benlysta)</i></b>	<b><i>Weekly</i></b>	<b><i>Week 2</i></b>

*Centers for Disease Control and Prevention*

**MMWR**

Morbidity and Mortality Weekly Report

Weekly / Vol. 71 / No. 7

February 18, 2022

## **Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2022**

Neil Murthy, MD<sup>1</sup>; A. Patricia Wodi, MD<sup>1</sup>; Henry Bernstein, DO<sup>2</sup>; Veronica McNally, JD<sup>3</sup>; Sybil Cineas, MD<sup>4</sup>; Kevin Ault, MD<sup>5</sup>

**Table 2** Recommended Adult Immunization Schedule by Medical Condition or Other Indication, United States, 2022

Vaccine	Pregnancy	Immuno-compromised (excluding HIV infection)	HIV infection percentage	on CD4 and count	Asplenia, complement deficiencies	End-stage renal disease, or on hemodialysis	Heart or lung disease; alcoholism <sup>1</sup>	Chronic liver disease	Diabetes	Health care personnel <sup>2</sup>	Men who have sex with men
			<15% or <200 mm <sup>3</sup>	≥15% and ≥200 mm <sup>3</sup>							
IIV4 or RIV4 or LAIV4			1 dose annually								
		Contraindicated	Precaution			1 dose annually					
Tdap or Td	1 dose Tdap each pregnancy	1 dose Tdap, then Td or Tdap booster every 10 years									
MMR	Contraindicated*	1 or 2 doses depending on indication									
VAR	Contraindicated*	2 doses			2 doses						
RZV		2 doses at age ≥19 years			2 doses at age ≥50 years						
HPV	Not Recommended*	3 doses through age 26 years			2 or 3 doses through age 26 years depending on age at initial vaccination or condition						
Pneumococcal (PCV15, PCV20, PPSV23)		1 dose PCV15 followed by PPSV23 OR 1 dose PCV20 (see notes)									
HepA		2 or 3 doses depending on vaccine									
HepB	3 doses (see notes)	2, 3, or 4 doses depending on vaccine or condition									
MenACWY		1 or 2 doses depending on indication, see notes for booster recommendations									
MenB	Precaution	2 or 3 doses depending on vaccine and indication, see notes for booster recommendations									
Hib		3 doses HSCT <sup>3</sup> recipients only	1 dose								

Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack
  Recommended vaccination for adults with an additional risk factor or another indication
  Recommended vaccination based on shared clinical decision-making
  Precaution—vaccination might be indicated if benefit of protection outweighs risk of adverse reaction
  Contraindicated or not recommended—vaccine should not be administered.
  No recommendation/Not applicable

\*Vaccinate after pregnancy.



Viracura

## Human papillomavirus vaccination

### Routine vaccination

- **HPV vaccination recommended for all persons through age 26 years:** 2- or 3-dose series depending on age at initial vaccination or condition:

### Special situations

- **Age ranges recommended above for routine and catch-up vaccination or shared clinical decision-making also apply in special situations**
  - **Immunocompromising conditions, including HIV infection:** 3-dose series, even for those who initiate vaccination at age 9 through 14 years.
  - **Pregnancy:** Pregnancy testing is not needed before vaccination; HPV vaccination is not recommended until after pregnancy; no intervention needed if inadvertently vaccinated while pregnant

## Pneumococcal vaccination

### Routine vaccination

- **Age 65 years or older** who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown: 1 dose PCV15 or 1 dose PCV20. If PCV15 is used, this should be followed by a dose of PPSV23 given at least 1 year after the PCV15 dose. A minimum interval of 8 weeks between PCV15 and PPSV23 can be considered for adults with an immunocompromising condition,\* cochlear implant, or cerebrospinal fluid leak to minimize the risk of invasive pneumococcal disease caused by serotypes unique to PPSV23 in these vulnerable groups.
- For guidance for patients who have already received a previous dose of PCV13 and/or PPSV23, see [www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm](http://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm).

### Special situations

- **Age 19–64 years** with certain underlying medical conditions or other risk factors\*\* who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown: 1 dose PCV15 or 1 dose PCV20. If PCV15 is used, this should be followed by a dose of PPSV23 given at least 1 year after the PCV15 dose. A minimum interval of 8 weeks between PCV15 and PPSV23 can be considered for adults with an immunocompromising condition,\* cochlear implant, or cerebrospinal fluid leak to minimize the risk of invasive pneumococcal disease caused by serotypes unique to PPSV23 in these vulnerable groups.
- For guidance for patients who have already received a previous dose of PCV13 and/or PPSV23, see [www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm](http://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm).

## Zoster vaccination

### Routine vaccination

- **Age 50 years or older:** 2-dose series RZV (Shingrix) 2–6 months apart (minimum interval: 4 weeks; repeat dose if administered too soon), regardless of previous herpes zoster or history of zoster vaccine live (ZVL, Zostavax) vaccination (administer RZV at least 2 months after ZVL)

### Special situations

- **Pregnancy:** There is currently no ACIP recommendation for RZV use in pregnancy. Consider delaying RZV until after pregnancy.
- **Immunocompromising conditions (including HIV):** RZV recommended for use in persons age 19 years or older who are or will be immunodeficient or immunosuppressed because of disease or therapy. For detailed information, see [www.cdc.gov/mmwr/volumes/71/wr/mm7103a2.htm](http://www.cdc.gov/mmwr/volumes/71/wr/mm7103a2.htm).

## Audience Poll

It is November and a 22 year old female patient with Rheumatoid Arthritis on Methotrexate who recently started Adalimumab is in your office for an annual exam. She's not had any vaccinations since childhood. Which of the following vaccination recommendations are correct (per the ACR)?

- A. Annual flu shot
- B. Annual flu shot- hold MTX for 2 weeks
- C. Annual flu shot- hold Humira for 2 weeks
- D. High dose annual flu shot, pneumococcal vaccination, recombinant VZV, HPV and Tdap- hold MTX for 2 weeks after
- D. None

# 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

Anne R. Bass,<sup>1</sup>  Eliza Chakravarty,<sup>2</sup> Elie A. Akl,<sup>3</sup> Clifton O. Bingham,<sup>4</sup>  Leonard Calabrese,<sup>5</sup>   
Laura C. Cappelli,<sup>4</sup>  Sindhu R. Johnson,<sup>6</sup>  Lisa F. Imundo,<sup>7</sup> Kevin L. Winthrop,<sup>8</sup>  Reuben J. Arasaratnam,<sup>9</sup>  
Lindsey R. Baden,<sup>10</sup> Roberta Berard,<sup>11</sup>  S. Louis Bridges Jr.,<sup>1</sup>  Jonathan T. L. Cheah,<sup>12</sup> Jeffrey R. Curtis,<sup>13</sup>   
Polly J. Ferguson,<sup>14</sup> Ida Hakkarinen,<sup>15</sup> Karen B. Onel,<sup>1</sup> Grayson Schultz,<sup>16</sup> Vidya Sivaraman,<sup>17</sup>  
Benjamin J. Smith,<sup>18</sup>  Jeffrey A. Sparks,<sup>10</sup>  Tiphonie P. Vogel,<sup>19</sup>  Eleanor Anderson Williams,<sup>20</sup>  
Cassandra Calabrese,<sup>5</sup> Joanne S. Cunha,<sup>21</sup> Joann Fontanarosa,<sup>22</sup> Miriah C. Gillispie-Taylor,<sup>19</sup>  
Elena Gkrouzman,<sup>12</sup>  Priyanka Iyer,<sup>23</sup> Kimberly S. Lakin,<sup>1</sup>  Alexandra Legge,<sup>24</sup> Mindy S. Lo,<sup>25</sup>   
Megan M. Lockwood,<sup>26</sup>  Rebecca E. Sadun,<sup>27</sup>  Namrata Singh,<sup>28</sup> Nancy Sullivan,<sup>22</sup> Herman Tam,<sup>29</sup>   
Marat Turgunbaev,<sup>30</sup> Amy S. Turner,<sup>30</sup>  and James Reston<sup>22</sup>

**Table 3.** Medication management at the time of non-live attenuated vaccine administration. Color table can be viewed in the online issue, which is available at <http://onlinelibrary.wiley.com/doi/10.1002/art.42386/abstract>.

	Influenza vaccination	Other non-live attenuated vaccinations
Methotrexate	Hold methotrexate for 2 weeks <i>after</i> vaccination*	Continue methotrexate
Rituximab	Continue rituximab†	Time vaccination for when the next rituximab dose is due, and then hold rituximab for at least 2 weeks after vaccination
Immunosuppressive medications other than methotrexate and rituximab	Continue immunosuppressive medication	Continue immunosuppressive medication

□ = Conditional recommendation.

\* Hold only if disease activity allows. Non-rheumatology providers, e.g., general pediatricians and internists, are encouraged to give the influenza vaccination and then consult with the patient's rheumatology provider about holding methotrexate to avoid a missed vaccination opportunity.

† Give influenza vaccination on schedule. Delay any subsequent rituximab dosing for at least 2 weeks after influenza vaccination if disease activity allows.

Recommendations	Level of evidence†	PICO	numbers
Expanded indications for specific vaccines in patients with RMDs receiving immunosuppression Influenza vaccination			
For patients with RMD age ≥65 years and patients with RMD age >18 and <65 years who are taking immunosuppressive medication, giving high-dose or adjuvanted influenza vaccination is <b>conditionally</b> recommended over giving regular-dose influenza vaccination.	PICO 9. Very low (indirect evidence only)‡	PICO 9. In patients with RMD age ≥65 years, is high-dose influenza vaccine more effective than seasonal regular-dose influenza vaccine?	728
	PICO 10. Very low (indirect evidence only)‡	PICO 10. In patients with RMD age ≥65 years, is adjuvanted influenza vaccine more effective than seasonal regular-dose influenza vaccine?	728

**Table 5.** Immunosuppressive medication management at the time of live attenuated virus vaccine administration\*

	Hold before live attenuated virus vaccine administration	Hold after live attenuated virus vaccine administration
Glucocorticoids†	4 weeks	4 weeks
Methotrexate, azathioprine‡	4 weeks	4 weeks
Leflunomide, mycophenolate mofetil, calcineurin inhibitors, oral cyclophosphamide	4 weeks	4 weeks
JAK inhibitors	1 week	4 weeks
TNF, IL-17, IL-12/23, IL-23, BAFF/BLyS inhibitors	1 dosing interval§	4 weeks
IL-6 pathway inhibitors	1 dosing interval¶	4 weeks
IL-1 inhibitors		
Anakinra	1 dosing interval¶	4 weeks
Riloncept	1 dosing interval¶	4 weeks
Canakinumab	1 dosing interval¶	4 weeks
Abatacept	1 dosing interval§	4 weeks
Anifrolumab	1 dosing interval§	4 weeks
Cyclophosphamide, intravenous	1 dosing interval§	4 weeks
Rituximab	6 months	4 weeks
IVIG#		
300–400 mg/kg	8 months	4 weeks
1 gm/kg	10 months	4 weeks
2 gm/kg	11 months	4 weeks

#### Pneumococcal vaccination

For patients with RMD age <65 years who are taking immunosuppressive medication, pneumococcal vaccination is **strongly** recommended.

#### Recombinant VZV vaccination

For patients with RMD age >18 years who are taking immunosuppressive medication, administering the recombinant VZV vaccine is **strongly** recommended.

#### HPV vaccination

For patients with RMD age >26 and <45 years who are taking immunosuppressive medication and are not previously vaccinated, vaccination against HPV is **conditionally** recommended.

Whether to hold immunosuppressive medication at the time of non-live attenuated vaccination to maximize vaccine immunogenicity, although holding medications could be associated with disease flare

For patients with RMD, *holding* methotrexate for 2 weeks after influenza vaccination is **conditionally** recommended, assuming disease activity allows.



## Vaccine Information Statements (VISs)

VIS Home > Current VISs

🏠 VIS Home

Current VISs

Respiratory Syncytial Virus  
Infection (RSV) VIS

What's New with VISs

About VISs

Dates of Current and Past VISs

VIS Barcodes

### Related Link

[Vaccines & Immunizations](#)

[Immunization Schedules](#)

# Respiratory Syncytial Virus (RSV) VIS

RSV Vaccine: What You Need to Know

[Print](#)

Current Edition Date: 7/24/2023

- [Print VIS](#) 📄 [2 pages]
- [RTF file](#) 📄 [3 pages]  
(For use in electronic systems)
- More information about [RSV](#)

## Why get vaccinated?

RSV vaccine can prevent lower respiratory tract disease caused by **respiratory syncytial virus (RSV)**. RSV is a common respiratory virus that usually causes mild, cold-like symptoms.

RSV is usually spread through direct contact with the virus, such as droplets from another person's cough or sneeze contacting your eyes, nose, or mouth. It can also be spread by touching a surface that has the virus on it, like a doorknob, and then touching your face before washing your hands.

### On This Page

[Why get vaccinated?](#)

[RSV vaccine](#)

[Talk with your health care provider](#)

[Risks of a vaccine reaction](#)

[What if there is a serious problem?](#)

[How can I learn more?](#)

CDC recommends **adults 60 years and older** may receive a single dose of RSV vaccine “based on discussions between the patient and health care provider.”



ELSEVIER

Contents lists available at ScienceDirect

# Contemporary Clinical Trials Communications

journal homepage: <http://www.elsevier.com/locate/conctc>



Research paper

## Design of an anti-inflammatory diet (ITIS diet) for patients with rheumatoid arthritis

Marta F. Bustamante<sup>a</sup>, Meritxall Agustín-Perez<sup>a</sup>, Francesca Cedola<sup>a</sup>, Roxana Coras<sup>a,c</sup>,  
Rekha Narasimhan<sup>a</sup>, Shahrokh Golshan<sup>b</sup>, Monica Guma<sup>a,c,\*</sup>

<sup>a</sup> Department of Medicine, University of California San Diego, San Diego, CA, USA

<sup>b</sup> Department of Psychiatry, University of California San Diego, San Diego, CA, USA

<sup>c</sup> Department of Medicine, Autonomous University of Barcelona, Plaça Clívia, 08193, Bellaterra, Barcelona, Spain



### ARTICLE INFO

#### Keywords:

Rheumatoid arthritis  
Diet design  
Anti-inflammatory diet  
ITIS diet  
Microbiome

### ABSTRACT

**Background:** Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that affects synovial joints, leading to inflammation, joint destruction, loss of function, and disability. Although recent pharmaceutical advances have improved treatment of RA, patients with RA often inquire about dietary interventions to improve RA symptoms, as they perceive rapid changes in their symptoms after consumption of certain foods. There is evidence that some ingredients have pro- or anti-inflammatory effects. In addition, recent literature has shown a link between diet and microbiome changes. Both diet and the gut microbiome are linked to circulating metabolites that may modulate inflammation. However, evidence of the effects of an anti-inflammatory and probiotic-rich diet in patients with RA is scarce. There is also a need for biological data to support its anti-inflammatory effects.

**Methods:** The main goal of this study is to delineate the design process for a diet tailored to our RA population. To achieve this goal, we collected information on diet, supplements, cooking methods, and intake of different ingredients for each patient. Different groups were interviewed, and their feedback was assessed to design a diet that incorporates suggested anti-inflammatory ingredients in a manner that was easy for patients to adopt based on their lifestyles and backgrounds.

**Results:** We designed a diet that includes a high intake of potential anti-inflammatory ingredients. Feedback from highly motivated patients was critical in constructing an anti-inflammatory diet (ITIS diet) with elevated adherence.

**Conclusion:** In order to tailor our diet, we surveyed our patients on several different parameters. We obtained important feedback on how feasible our ITIS diet is for RA patients. Using this feedback, we made minor improvements and finalized the design of the ITIS diet. This diet is being used in an on-going pilot study to determine their anti-inflammatory effect in pain and joint swelling in RA patients.

**Trial registration:** Not applicable.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997513/pdf/main.pdf>

**Table 1**  
Strategies and recommendations in the ITIS diet.

Main recommendations (WHAT/WHAT FOR)	Based on (WHY)	Diet strategies (HOW)
<ul style="list-style-type: none"> <li>• Lower the omega6/3 PUFA ratio to 2:1</li> <li>• Increase intake of MUFA</li> <li>• Decrease intake of pro-inflammatory FA such as trans-FA and saturated FA (present in dairy products, red meat and processed food)</li> </ul>	<ul style="list-style-type: none"> <li>• A low omega 6/3 PUFA ratio reduces inflammation and improves autoimmunity symptoms [28–32].</li> <li>• MUFA found in nuts, avocado, sesame and olive oil have beneficial effect in RA [33,34]</li> <li>• Industrially produced trans-FA increase inflammatory markers and saturated FA increase inflammation [15–17].</li> </ul>	<ul style="list-style-type: none"> <li>• The diet must contain fatty fish such as sardines, tuna, twice per week, daily intake of chia seeds and flaxseed oil.</li> <li>• Daily intake of nuts, avocado, and/or sesame seeds or tahini</li> <li>• Avoid pre-cooked food, red meat and processed meat. Cook by baking, boiling or vapor. Avoid frying for long periods since it modifies PUFA to trans-FA [60].</li> </ul>
<ul style="list-style-type: none"> <li>• High intake of prebiotics</li> <li>• Daily intake of probiotics</li> </ul>	<ul style="list-style-type: none"> <li>• Dietary fiber, whole-grain complex carbohydrates, and sugar alcohols present in fruits are prebiotics that support healthy microbiome [11,12] and increases SCFA production improving immunity [13].</li> <li>• Probiotics including yogurt reduce the levels of the pro-inflammatory cytokines and improves disease activity in RA [10,52, 53]</li> </ul>	<ul style="list-style-type: none"> <li>• Daily green leafy vegetables (arugula, lettuce, broccoli, zucchini, Green beans) and fruits (prebiotic source).</li> <li>• Daily home-made green juice (made of fruits and green vegetables) (prebiotic source).</li> <li>• Promote whole grains and avoid refined flours (prebiotic source).</li> <li>• Daily yogurt (a brand that contains <i>Lactobacillus Casei</i> among other species (Chobani) and miso</li> </ul>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997513/pdf/main.pdf>

- Help digestion of large proteins in the gut and avoid unnecessary fermentation
- Fiber consumption and enzymatic fruits will reduce colonic transit, and will help protein digestion
- Bromelain and papain were shown to have an anti-inflammatory effect as well [40–42].
- Large proteins in dairy products are not completely digested and can feed proteolytic bacteria, resulting in the production of pro-inflammatory metabolites [66].
- Turmeric, black pepper and ginger have antioxidant and anti-inflammatory actions [43–46]
- Black pepper increases bioavailability of curcuma [46,47]
- High salt intake is associated with the risk of arthritis and has been related to autoimmunity [67,68].
- *Solanaceae* vegetables contain glycoalkaloids. Glycoalkaloids have been reported to affect
- Daily enzymatic fruit: pineapple, mango or papaya (source of bromelain, papain and other proteolytic enzymes)
- Disassociate consumption of proteins from grains
- Increase fiber intake
- Substitute plant-based milks (almond, rice, coconut) for dairy.
- Condiment with turmeric, black pepper and ginger.
- Turmeric and black pepper should be used at the same time.
- Low salt intake by eliminating precooked food
- Avoid the consumption of eggplant, tomatoes and potatoes and increase consumption
- Condiment with anti-inflammatory spices
- Eliminate salt
- Substitute vegetables with potential anti-inflammatory

- Decrease consumption of red meat.
- Reduce consumption of gluten
- Avoid sugars, sugary foods and sugary beverages
- Substitute green tea for coffee
- Increase the intake of antioxidants, phytochemicals and flavonoids
- It contains high levels of choline, which is the precursor of the inflammatory metabolite TMAO [5,6] and saturated FA.
- Gluten has been associated with inflammatory states [14].
- Pseudocereals and whole grains reduce inflammation [69,70]
- Sugary foods and beverages are associated to obesity, microbiome changes and low-grade inflammatory state [71].
- Green tea contains polyphenols which decrease pro-inflammatory cytokines in animal models and *in vitro* models of RA [48–50,72,73]
- Some studies suggest that coffee consumption may increase the risk of developing RA [74].
- Antioxidants, phytochemicals, flavonoids and vitamins were suggested to have anti-inflammatory properties [35–39].
- Introduce legumes (red, white beans, lentils or garbanzo), poultry and white fish, 2–3 days a week each. Avoid red meat.
- Substitute whole grains such as rye, corn, oats or quinoa for refined wheat.
- Substitute honey for sugar. Avoid soda and juices.
- Daily green tea
- Vegetables, fruits, apple cider vinegar, whole grains contain high amounts of antioxidants, phytochemicals, vitamins, and flavonoids.
- Daily home-made green juice (made of fruits and green vegetables)

**Table 2**  
Final version of the ITIS diet.

		Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
7-8 am	SMOOTHIE	Coconut milk, mango, papaya, pineapple	Pear, lemon, yogurt, vanilla, water	Grapes, celery, spinach, cucumber, lime, water	Almond or oat milk, spinach, strawberries, pear, ginger, chia seeds, cinnamon	Spinach, ginger, turmeric, papaya, flaxseeds, banana, water	Papaya, spinach, almond milk, turmeric, chia seeds, honey	Parsley, pineapple, strawberries, water
7-8 am	BREAKFAST	1-2 spoonful of oats with non-dairy milk (oat milk, almond milk or rice milk). Add berries (optional). Green tea infusion.	1-2 corn tortillas, spread with avocado, sesame seeds, and flaxseed oil. Green tea infusion.	1 -2 corn tortillas with tahini (sesame seed extract) with ¼ teaspoon of honey. Green tea infusion	1-2 spoons of oat with non-dairy milk (oat, almond or rice milk. Add berries (optional). Green tea infusion.	1-2 corn tortillas, spread with avocado, sesame seeds, and flaxseed oil. Green tea infusion.	1 -2 corn tortillas with tahini (sesame seed extract) with ¼ teaspoon of honey. Green tea infusion	1-2 corn tortillas, spread with avocado, sesame seeds, and linseed oil. Green tea infusion.
10-11 a.m.	SNACK	Plain yogurt (Chobani Brand, no sugar added)	Plain yogurt (Chobani Brand, no sugar added)	Plain yogurt (Chobani Brand, no sugar added)	Plain yogurt (Chobani Brand, no sugar added)	Plain yogurt (Chobani Brand, no sugar added)	Plain yogurt (Chobani Brand, no sugar added)	Plain yogurt (Chobani Brand, no sugar added)
12-1 pm	LUNCH	OPTION 1: Salad (generous plate) OPTION 2: Grains with vegetables OPTION 3: Legumes with vegetables						
4 p.m.	SNACK	Mango, papaya, pineapple, apple, pear or banana +4 walnuts	Mango, papaya, pineapple, apple, pear or banana +4 walnuts	Mango, papaya, pineapple, apple, pear or banana +4 walnuts	Mango, papaya, pineapple, apple, pear or banana +4 walnuts	Mango, papaya, pineapple, apple, pear or banana +4 walnuts	Mango, papaya, pineapple, apple, pear or banana +4 walnuts	Mango, papaya, pineapple, apple, pear or banana +4 walnuts
6-7 pm	DINNER	OPTION 1: Vegetable soup/cream + protein OPTION 2: Miso soup + baked/steamed/grilled vegetables + protein OPTION 3: Salad + protein						

# ITIS: A Supercharged Mediterranean Diet for RA



A new approach to a popular diet shows a positive effect on the microbiome, a key player in inflammatory arthritis severity and outcomes.

By **Linda Rath**

Diets fall in and out of favor, but the Mediterranean diet has stood the test of time. Decades of research have shown that a plant-based mix, including vegetables, fruit, legumes, olive oil, fish and whole grains, can improve or prevent many chronic diseases, including heart disease, type 2 diabetes and arthritis.

Scientists trace the diet's benefits in part to its positive effect on the **microbiome** — the rich ecosystem of microbes, or microorganisms, that inhabit our bodies, especially the gut.

What you eat can encourage or inhibit the growth of certain types of gut bacteria, increase or decrease overall diversity and influence metabolites the microbes produce, which are key players in activating inflammation. An unhealthy microbiome — one that's less diverse and unbalanced — is associated with autoimmune diseases like rheumatoid arthritis (RA) in susceptible people.

## Mediterranean Diet 2.0

"We know the **Mediterranean diet** is good for patients with rheumatoid arthritis," says Monica Guma, MD, a rheumatologist and researcher at the University of California, San Diego. "But there also might be something better." That something is what she calls the ITIS diet. It's the Mediterranean diet supercharged with anti-inflammatory foods and herbs that may improve gut health and arthritis symptoms.

She and her colleagues spent a year designing the diet. At four different stages, they consulted patients to make sure the diet was affordable and was one they could stick with for the two-week study period. They made a few changes as needed.

# Questions?



[Erin.Bauer@virginamason.org](mailto:Erin.Bauer@virginamason.org)

Phone: (206) 223-6824

Fax: (206) 625-7288

Pager: (206) 540-3499